About aptevo therapeutics inc - APVO
Aptevo Therapeutics, Inc. is a clinical-stage biotechnology company, which engages on developing novel immunotherapies for the treatment of cancer. Its pipeline APVO436, ALG.APV-527, and APVO603 were developed based on the ADAPTIR modular protein platform technology and APVO442 was developed based on the new ADAPTIR-FLE platform technology. The ADAPTIR and ADAPTIR-FLEX are capable of generating differentiated bispecific and multi-specific antibodies with potentially unique mechanisms of action for the treatment of different types of cancer. The company was founded in February 2016 and is headquartered in Seattle, WA.
APVO At a Glance
Aptevo Therapeutics, Inc.
2401 4th Avenue
Seattle, Washington 98121
| Phone | 1-206-838-0500 | Revenue | 0.00 | |
| Industry | Biotechnology | Net Income | -25,967,000.00 | |
| Sector | Health Technology | Employees | 36 | |
| Fiscal Year-end | 12 / 2026 | |||
| View SEC Filings |
APVO Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | 0.541 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | 0.538 |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | -0.33 |
APVO Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | -721,305.556 |
| Receivables Turnover | N/A |
| Total Asset Turnover | N/A |
APVO Liquidity
| Current Ratio | 3.815 |
| Quick Ratio | 3.815 |
| Cash Ratio | 3.573 |
APVO Profitability
| Gross Margin | N/A |
| Operating Margin | N/A |
| Pretax Margin | N/A |
| Net Margin | N/A |
| Return on Assets | -119.156 |
| Return on Equity | -234.613 |
| Return on Total Capital | -117.978 |
| Return on Invested Capital | -170.119 |
APVO Capital Structure
| Total Debt to Total Equity | 26.633 |
| Total Debt to Total Capital | 21.031 |
| Total Debt to Total Assets | 16.536 |
| Long-Term Debt to Equity | 21.65 |
| Long-Term Debt to Total Capital | 17.097 |